- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00003674
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients with advanced cancer that has not responded to previous treatment. It is not yet known if standard therapy is more effective with or without dalteparin in treating advanced breast, lung, colorectal, and prostate cancer.
PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard therapy with or without dalteparin in treating patients who have advanced breast, lung, colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone therapy.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES: I. Compare the effect of low molecular weight heparin (dalteparin) plus standard therapy versus standard therapy alone on the overall survival rate of patients with advanced cancers. II. Compare the toxic effects of these regimens and the effect on the quality of life of these patients. III. Assess the incidence of symptomatic thrombotic events such as deep venous thrombosis (DVT), pulmonary embolus (PE), and clotted catheters in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to prognostic index (good vs bad vs unsure), current therapy (systemic vs radiation vs both vs none), age (50 or under vs over 50), disease site (breast vs colon vs small cell lung vs nonsmall cell lung vs prostate), history of prior thrombotic event over 1 year ago (yes vs no), and gender. Patients are randomized to receive low molecular weight heparin (dalteparin) plus standard therapy or standard therapy alone.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85259-5404
- CCOP - Scottsdale Oncology Program
-
-
Illinois
-
Urbana, Illinois, Forenede Stater, 61801
- CCOP - Carle Cancer Center
-
-
Iowa
-
Cedar Rapids, Iowa, Forenede Stater, 52403-1206
- CCOP - Cedar Rapids Oncology Project
-
Des Moines, Iowa, Forenede Stater, 50309-1016
- CCOP - Iowa Oncology Research Association
-
Sioux City, Iowa, Forenede Stater, 51101-1733
- Siouxland Hematology-Oncology
-
-
Kansas
-
Wichita, Kansas, Forenede Stater, 67214-3882
- CCOP - Wichita
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70121
- CCOP - Ochsner
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- CCOP - Ann Arbor Regional
-
-
Minnesota
-
Duluth, Minnesota, Forenede Stater, 55805
- CCOP - Duluth
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, Forenede Stater, 56303
- CentraCare Clinic
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68131
- CCOP - Missouri Valley Cancer Consortium
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Medcenter One Health System
-
Fargo, North Dakota, Forenede Stater, 58122
- CCOP - Merit Care Hospital
-
Grand Forks, North Dakota, Forenede Stater, 58201
- Altru Health Systems
-
-
Ohio
-
Toledo, Ohio, Forenede Stater, 43623-3456
- CCOP - Toledo Community Hospital Oncology Program
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822-2001
- CCOP - Geisinger Clinic and Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57709
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Forenede Stater, 57105-1080
- CCOP - Sioux Community Cancer Consortium
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS: Histologically or cytologically proven breast, lung, colorectal, or prostate cancer that has failed prior chemotherapy or hormone therapy No active CNS metastases Hormone receptor status: Not specified
PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3500/mm3 Platelet count at least 150,000/mm3 Fibrinogen above lower limits of normal Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3 times ULN Prothrombin time no greater than 1.5 times ULN Active partial thromboplastin time no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No history of heparin associated thrombocytopenia At least 1 year since prior thromboembolic phenomenon such as deep venous thrombosis, pulmonary embolus, or clotted catheter No prior intolerance of unfractionated or low molecular weight heparin
PRIOR CONCURRENT THERAPY: No concurrent anticoagulation therapy No concurrent enrollment on systemic or radiation therapy study (therapy off study allowed)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: dalteparin + standard therapy
Patients receive dalteparin by subcutaneous injection once daily plus standard therapy.
Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity.
Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years.
Patients are followed monthly for 1 year, then every 3 months for 2 years.
|
|
Aktiv komparator: standard therapy
Patients receive standard therapy alone.
Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity.
Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years.
Patients are followed monthly for 1 year, then every 3 months for 2 years.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Samlet overlevelsesrate
Tidsramme: Op til 5 år
|
Op til 5 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall quality of life
Tidsramme: Up to 5 years
|
Up to 5 years
|
Assess the incidence of symptomatic thrombotic events such as deep venous thrombosis (DVT), pulmonary embolus (PE), and clotted catheters
Tidsramme: Up to 5 years
|
Up to 5 years
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- stadium IV brystkræft
- tilbagevendende brystkræft
- tilbagevendende ikke-småcellet lungekræft
- småcellet lungekræft i omfattende stadie
- tilbagevendende småcellet lungekræft
- stadium IV prostatacancer
- tilbagevendende prostatakræft
- fase IV ikke-småcellet lungekræft
- stadium IV endetarmskræft
- stadium IV tyktarmskræft
- tilbagevendende tyktarmskræft
- tilbagevendende endetarmskræft
- veno-okklusiv sygdom
Yderligere relevante MeSH-vilkår
- Hudsygdomme
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Genitale neoplasmer, mandlige
- Brystsygdomme
- Prostatasygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Brystneoplasmer
- Prostatiske neoplasmer
- Lungeneoplasmer
- Molekylære mekanismer for farmakologisk virkning
- Fibrinolytiske midler
- Fibrinmodulerende midler
- Antikoagulanter
- Heparin, lavmolekylær vægt
- Tinzaparin
- Dalteparin
Andre undersøgelses-id-numre
- NCCTG-979251
- CDR0000066775 (Registry Identifier: PDQ (Physician Data Query))
- NCI-P98-0139
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkendtHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
Kliniske forsøg med dalteparin
-
PfizerAfsluttetDiabetisk fodsårCanada, Grækenland, Østrig, Finland, Polen, Sverige, Den Russiske Føderation, Norge, Spanien, Italien, Det Forenede Kongerige, Danmark, Litauen, Belgien, Tyskland, Ukraine, Tjekkiet
-
PfizerAfsluttetVenøs tromboembolismeForenede Stater, Norge, Den Russiske Føderation, Slovenien, Spanien
-
Ontario Clinical Oncology Group (OCOG)PfizerAfsluttetVenøs tromboembolisme | HjernetumorerForenede Stater, Canada, Australien, Italien
-
Medical University of ViennaAfsluttet
-
Velindre NHS TrustUkendtLungekræft | TromboemboliDet Forenede Kongerige
-
PfizerAfsluttetKræftForenede Stater, Canada, Spanien, Østrig, Holland
-
Thomas Decker ChristensenAfsluttet
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)AfsluttetTumorer i hjernen og centralnervesystemetForenede Stater
-
M.D. Anderson Cancer CenterBrookdale University Hospital Medical Center; Josephine Ford Cancer CenterAfsluttetNeoplasmer | Dyb venetromboseForenede Stater
-
University Hospital, Basel, SwitzerlandAfsluttet